TSQM individual domain baseline, day 30, and day 90/EOS mean values and percent change from baseline after switch to avatrombopag
| . | Total population (N = 60)∗ . | Eltrombopag switched (n = 38)† . | Romiplostim switched (n = 22)‡ . | |||
|---|---|---|---|---|---|---|
| Domain score . | Change from baseline . | Domain score . | Change from baseline . | Domain score . | Change from baseline . | |
| Convenience | ||||||
| Baseline§ | 71.8 (21.8) | – | 74.0 (19.4) | – | 67.9 (25.2) | – |
| Day 30 | 84.9 (15.5) | 13.1 (24.8) | 83.5 (15.4) | 9.5 (23.0) | 87.5 (15.6) | 19.4 (27.2) |
| Day 90 | 85.7 (15.6) | 13.5 (24.7) | 84.2 (14.9) | 9.7 (20.8) | 88.3 (17.0) | 20.3 (29.9) |
| Effectiveness | ||||||
| Baseline§ | 66.7 (22.3) | – | 62.3 (23.3) | – | 74.0 (18.7) | – |
| Day 30 | 76.0 (19.2) | 10.1 (28.5) | 77.9 (18.8) | 16.2 (27.7) | 72.5 (19.9) | −0.6 (27.5) |
| Day 90 | 81.1 (20.4) | 14.4 (27.7) | 80.3 (21.8) | 17.1 (29.5) | 82.5 (18.0) | 9.4 (24.2) |
| Global satisfaction | ||||||
| Baseline§ | 69.0 (18.8) | – | 66.4 (19.0) | – | 73.4 (18.1) | – |
| Day 30 | 77.6 (17.4) | 8.6 (21.8) | 79.6 (17.5) | 12.2 (21.1) | 73.9 (17.1) | 2.1 (22.1) |
| Day 90 | 82.6 (18.6) | 14.2 (20.0) | 82.2 (16.8) | 15.7 (19.3) | 83.2 (22.0) | 11.4 (21.4) |
| Side effects | ||||||
| Baseline§ | 88.5 (24.1) | – | 86.7 (27.3) | – | 91.5 (17.8) | – |
| Day 30 | 93.5 (15.9) | 5.0 (24.8) | 93.1 (16.4) | 6.4 (25.1) | 94.4 (15.2) | 2.5 (24.7) |
| Day 90 | 96.2 (12.3) | 8.3 (22.9) | 94.8 (14.6) | 9.0 (24.8) | 98.8 (5.6) | 6.9 (19.7) |
| . | Total population (N = 60)∗ . | Eltrombopag switched (n = 38)† . | Romiplostim switched (n = 22)‡ . | |||
|---|---|---|---|---|---|---|
| Domain score . | Change from baseline . | Domain score . | Change from baseline . | Domain score . | Change from baseline . | |
| Convenience | ||||||
| Baseline§ | 71.8 (21.8) | – | 74.0 (19.4) | – | 67.9 (25.2) | – |
| Day 30 | 84.9 (15.5) | 13.1 (24.8) | 83.5 (15.4) | 9.5 (23.0) | 87.5 (15.6) | 19.4 (27.2) |
| Day 90 | 85.7 (15.6) | 13.5 (24.7) | 84.2 (14.9) | 9.7 (20.8) | 88.3 (17.0) | 20.3 (29.9) |
| Effectiveness | ||||||
| Baseline§ | 66.7 (22.3) | – | 62.3 (23.3) | – | 74.0 (18.7) | – |
| Day 30 | 76.0 (19.2) | 10.1 (28.5) | 77.9 (18.8) | 16.2 (27.7) | 72.5 (19.9) | −0.6 (27.5) |
| Day 90 | 81.1 (20.4) | 14.4 (27.7) | 80.3 (21.8) | 17.1 (29.5) | 82.5 (18.0) | 9.4 (24.2) |
| Global satisfaction | ||||||
| Baseline§ | 69.0 (18.8) | – | 66.4 (19.0) | – | 73.4 (18.1) | – |
| Day 30 | 77.6 (17.4) | 8.6 (21.8) | 79.6 (17.5) | 12.2 (21.1) | 73.9 (17.1) | 2.1 (22.1) |
| Day 90 | 82.6 (18.6) | 14.2 (20.0) | 82.2 (16.8) | 15.7 (19.3) | 83.2 (22.0) | 11.4 (21.4) |
| Side effects | ||||||
| Baseline§ | 88.5 (24.1) | – | 86.7 (27.3) | – | 91.5 (17.8) | – |
| Day 30 | 93.5 (15.9) | 5.0 (24.8) | 93.1 (16.4) | 6.4 (25.1) | 94.4 (15.2) | 2.5 (24.7) |
| Day 90 | 96.2 (12.3) | 8.3 (22.9) | 94.8 (14.6) | 9.0 (24.8) | 98.8 (5.6) | 6.9 (19.7) |
Data are shown as mean (SD). The scoring scale for each domain of the TSQM ranges from 0 to 100.
Baseline, n = 59; day 30, n = 56; day 90, n = 57.
Baseline, n = 37; day 30, n = 36; day 90, n = 37.
Baseline, n = 22; day 30, n = 20; day 90, n = 20.
Baseline is defined as the last nonmissing assessment done on or before the start of avatrombopag on day 1.